12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Company News  |  Deals

SkyePharma, Theravance, GlaxoSmithKline deal

SkyePharma said that it is entitled to receive from GlaxoSmithKline a low single-digit royalty on net sales of Breo Ellipta fluticasone furoate/vilanterol, capped at £6 million ($9.2 million) per annum. Earlier this month, FDA approved an NDA from GSK for the product as maintenance therapy for airflow obstruction in...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >